Breakout Setups
LQDA appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
LIQUIDIA CORP (LQDA) Stock Price & Overview
NASDAQ:LQDA • US53635D2027
Current stock price
38.71 USD
-0.14 (-0.36%)
At close:
38.71 USD
0 (0%)
After Hours:
The current stock price of LQDA is 38.71 USD. Today LQDA is down by -0.36%. In the past month the price increased by 8.43%. In the past year, price increased by 182.14%.
LQDA Key Statistics
52-Week Range11.85 - 46.67
Current LQDA stock price positioned within its 52-week range.
1-Month Range34.21 - 40.76
Current LQDA stock price positioned within its 1-month range.
- Market Cap
- 3.411B
- P/E
- N/A
- Fwd P/E
- 14.32
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
LQDA Stock Performance
Today
-0.36%
1 Week
+3.61%
1 Month
+8.43%
3 Months
+2.06%
Longer-term
6 Months +72.20%
1 Year +182.14%
2 Years +201.24%
3 Years +476.90%
5 Years +1,263.03%
10 Years N/A
LQDA Stock Chart
LQDA Stock Screens
LQDA currently appears in the following ChartMill screener lists.
Minervini Stocks
LQDA is part of our Minervini Stocks list, indicating it shows strong fundamental growth characteristics and technical strength.
LQDA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 95.04% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LQDA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LQDA. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LQDA Earnings
On March 5, 2026 LQDA reported an EPS of 0.17 and a revenue of 92.02M. The company missed EPS expectations (-7.63% surprise) and beat revenue expectations (7.87% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported$0.17
Revenue Reported92.021M
EPS Surprise -7.63%
Revenue Surprise 7.87%
LQDA Forecast & Estimates
15 analysts have analysed LQDA and the average price target is 51.68 USD. This implies a price increase of 33.51% is expected in the next year compared to the current price of 38.71.
For the next year, analysts expect an EPS growth of 433.83% and a revenue growth 291.99% for LQDA
Analysts
Analysts82.67
Price Target51.68 (33.51%)
EPS Next Y433.83%
Revenue Next Year291.99%
LQDA Groups
Sector & Classification
LQDA Financial Highlights
Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 51.5% compared to the year before.
Income Statements
Revenue(TTM)158.32M
Net Income(TTM)-68.92M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.02% | ||
| ROE | -154.03% | ||
| Debt/Equity | 2.97 |
Chartmill High Growth Momentum
EPS Q2Q%136.96%
Sales Q2Q%3054.65%
EPS 1Y (TTM)51.5%
Revenue 1Y (TTM)1031.18%
LQDA Ownership
Ownership
Inst Owners68.36%
Shares88.11M
Float75.07M
Ins Owners4.19%
Short Float %15.8%
Short Ratio7.69
LQDA Latest News, Press Relases and Analysis
12 days ago - By: Chartmill
LQDA Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.38 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.56 | 297.058B | ||
| PFE | PFIZER INC | 9.07 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.17 | 118.543B | ||
| ZTS | ZOETIS INC | 17.12 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 27.937B | ||
| VTRS | VIATRIS INC | 5.58 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.91 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.5 | 4.606B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LQDA
Company Profile
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 216 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Company Info
IPO: 2018-07-26
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560 US
CEO: Neal Fowler
Employees: 216
Phone: 19193284400
LIQUIDIA CORP / LQDA FAQ
What does LIQUIDIA CORP do?
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 216 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
What is the stock price of LIQUIDIA CORP today?
The current stock price of LQDA is 38.71 USD. The price decreased by -0.36% in the last trading session.
Does LIQUIDIA CORP pay dividends?
LQDA does not pay a dividend.
How is the ChartMill rating for LIQUIDIA CORP?
LQDA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists LQDA stock?
LQDA stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for LQDA stock?
LIQUIDIA CORP (LQDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
Is LIQUIDIA CORP (LQDA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LQDA.